Jazz Pharmaceuticals Q2 2020 Earnings Report
Key Takeaways
Jazz Pharmaceuticals announced strong Q2 2020 financial results, with total revenues increasing by 5% year-over-year. The company highlighted the FDA approval of Xywav and the launch of Zepzelca. The company also updated its 2020 financial guidance, increasing total revenue to a range of $2.225 billion to $2.325 billion and GAAP EPS to $3.40 - $4.85.
Total revenues increased 5% compared to the second quarter of 2019.
Xyrem net product sales increased 8% to $446.8 million.
Sunosi net product sales were $8.6 million, compared to $1.9 million in the first quarter of 2020.
Zepzelca received accelerated approval by FDA and was launched in the U.S.
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Forward Guidance
Jazz Pharmaceuticals updated its full year 2020 financial guidance, reflecting the company's current and future expected operational performance, including the impact of COVID-19.